Megatherapy and stem cell transplantation for Ewing's family of tumors: A critical review of current literature

Abstract:  Although a multimodal approach consisting of chemotherapy and local control with surgery and/or radiation has improved survival in children with Ewing's sarcoma family of tumors, the prognosis for patients with high‐risk disease remains poor. More aggressive treatments with high‐dose myeloablative chemotherapy followed by stem cell rescue have been utilized in an attempt to improve survival in these patients. Although many studies have been published, it is difficult to interpret the data since patient populations were heterogeneous with respect to disease stage, prior therapy, conditioning and stem cell source. Furthermore, there was no uniform definition of high risk, the sample sizes were small and most studies lacked appropriate control groups. Assessment of the utility of megatherapy will require prospective controlled studies.

[1]  J. Haerting,et al.  High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Donaldson,et al.  Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. , 2003, The New England journal of medicine.

[3]  O. Delattre,et al.  Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Ladanyi,et al.  High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  L. Helman,et al.  Targeting pediatric malignancies for T cell-mediated immune responses , 2000, Current oncology reports.

[6]  H Bönig,et al.  In vivo cytokine responses to interleukin-2 immunotherapy after autologous stem cell transplantation in children with solid tumors , 2000, Bone Marrow Transplantation.

[7]  D. Hawkins,et al.  Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors. , 2000, Medical and pediatric oncology.

[8]  H. Kovar,et al.  Low incidence of molecular evidence for tumour in PBPC harvests from patients with high risk Ewing tumours , 1999, Bone Marrow Transplantation.

[9]  W. Winkelmann,et al.  Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  M. Kastan,et al.  Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing’s sarcoma , 1998, Bone Marrow Transplantation.

[11]  R. Souhami,et al.  High-dose busulphan/melphalan with autologous stem cell rescue in Ewing’s sarcoma , 1997, Bone Marrow Transplantation.

[12]  N. Schachar,et al.  High-dose melphalan +/- total body irradiation and autologous hematopoietic stem cell rescue for adult patients with Ewing's sarcoma or peripheral neuroectodermal tumor. , 1996, Bone marrow transplantation.

[13]  S. Burdach,et al.  Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. , 1995, Bone marrow transplantation.

[14]  S. Steinberg,et al.  Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Burdach,et al.  Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Venzon,et al.  Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. , 1991, International journal of radiation oncology, biology, physics.

[17]  Y. Sato,et al.  Miliary pulmonary neuroblastoma: A risk of autologous bone marrow transplantation? , 1988, Cancer.

[18]  W. Enneking,et al.  High-risk Ewing's sarcoma: end-intensification using autologous bone marrow transplantation. , 1988, International journal of radiation oncology, biology, physics.

[19]  Michael J. Campbell,et al.  Statistical tables for the design of clinical trials , 1987 .